论文部分内容阅读
目的:探讨瑞舒伐他汀与阿托伐他汀治疗冠心病的临床疗效,并进行比较。方法:选取2015年1月到2016年1月于我院就诊的冠心病患者共68例,将患者随机分为两组,观察组和对照组患者各34例,对照组患者进行阿托伐他汀治疗;观察组患者采用瑞舒伐他汀进行治疗,比较两组冠心病患者的治疗效果。结果:观察组34例患者在接受瑞舒伐他汀治疗之后,总有效率为94.12%;对照组患者在接受阿托伐他汀治疗之后,总有效率为70.59%。观察组的总有效率明显高于对照组,组间治疗效果比较具有明显差异,P<0.05。结论:临床上在治疗冠心病时,可以采用瑞舒伐他汀的治疗方法,能有效改善患者治疗效果,患者经过瑞舒伐他汀治疗之后的不良反应较少,获得非常理想的治疗效果,值得在临床上大力推广。
Objective: To investigate the clinical efficacy of rosuvastatin and atorvastatin in the treatment of coronary heart disease and to compare them. Methods: A total of 68 CHD patients were selected from January 2015 to January 2016 in our hospital. The patients were randomly divided into two groups, 34 cases in the observation group and control group, and the patients in the control group were treated with atorvastatin The patients in the observation group were treated with rosuvastatin, and the treatment effect of two groups of patients with coronary heart disease was compared. Results: The total effective rate was 94.12% in observation group 34 patients after receiving rosuvastatin treatment; in control group the total effective rate was 70.59% after receiving atorvastatin. The total effective rate of the observation group was significantly higher than that of the control group, with significant differences in the treatment effect between the two groups (P <0.05). Conclusion: In clinical treatment of coronary heart disease, the treatment of rosuvastatin can be used, which can effectively improve the therapeutic effect of patients. The adverse reactions after treatment with rosuvastatin are few and the ideal therapeutic effect is worth Promote clinically.